BackNeumora Therapeutics Overview
Neumora Therapeutics Inc.

Neumora Therapeutics Discounted Cash Flow

DCF fair value estimate for Neumora Therapeutics: $1.1.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$1.11

Current Fair Value

$1.11
↓ 34.8% Downside

Overvalued by 34.8% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

Neumora Therapeutics (NMRA) FAQ

As of the most recent data, NMRA shows a DCF fair value of $1.1. Scroll down for historical charts and peer comparison views.

Neumora Therapeutics's DCF reading of $1.1 (34.8% overvalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether Neumora Therapeutics's recent cash-flow history supports the assumptions.

Besides this discounted cash flow page, Stockcircle has Neumora Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $1.1) with ownership activity and broader fundamentals.